Development and Evaluation of Orally Disintegrating Tablet by Direct Compression Method

The aim and objective of orally disintegrating tablets by direct compression method was emerged from desired to provide patient with a conventional mean of taking their medication. Difficulty in swallowing (Dysphagia) is a common problem of all age groups, especially elderly and pediatrics, because of physiological changes associated with these groups of patients. In the present work Ondansetron was chosen as a model drug. Ondansetron is a selective serotonin 5HT3 receptor antagonist. It is widely used in the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. It is also used for prevention and treatment of postoperative nausea and vomiting. Although it is commonly used drug but major problem is its bitterness. In the present work, taste masking of Ondansetron was carried out by adding trusil lemon lime ASV, peppermint powder as flavouring agent and aspartame as sweetening agent, using croscarmellose sodium, sodium starch glycolate, crospovidone as superdisintegrant while other formulation component kept constant. Nine formulations F1-F9 were prepared by varying the concentration of superdisintegrant and keeping other constant. The total weight of tablet was kept constant (100mg) and drug content was 4mg in case of all formulations. The Formulation containing Crospovidone (20%, 25% and 30%) showed lowest disintegration time, wetting time, dispersion time. All the formulation release more than 80% of drug within 10min which prove its fast dissolving action. Based on dissolution rate superdisintegrants can be ranked as Crospovidone > Sodium starch glycolate > Croscarmellose sodium. Among all the formulated tablets containing 25% crosspovidone showed good compressibility, flowablity and less friability, it also showed less disintegration, wetting time, dispersion time and percentage cumulative release of drug was 99.47% in 10min. It was concluded that ideal bitterless orally disintegrating Ondansetron tablet was prepared successfully with patient acceptabilility.